Which Drugs Increase Gastrointestinal Motility?

Several classes of prescription drugs increase gastrointestinal motility, each targeting different receptors and mechanisms along the gut wall. The most commonly used are dopamine antagonists like metoclopramide, serotonin receptor agonists like prucalopride, and the antibiotic erythromycin repurposed at low doses for its effect on motilin receptors. Beyond these mainstays, newer agents act on ghrelin receptors, chloride channels, and bile acid transporters, giving clinicians a broader toolkit than ever for sluggish guts. The choice depends on which part of the digestive tract needs help, how long the treatment will last, and what side effects you can tolerate.

Dopamine Antagonists

Metoclopramide is probably the drug most people associate with speeding up the gut. It works by blocking dopamine receptors in the upper GI tract, which removes an inhibitory brake on stomach contractions and helps food move from the stomach into the small intestine faster. It also has some action on serotonin receptors, giving it a dual mechanism. In the United States, metoclopramide remains the only FDA-approved drug specifically for diabetic gastroparesis, a condition where nerve damage slows stomach emptying.

The catch is its side-effect profile. Because metoclopramide crosses into the brain, it can cause a range of neurological problems. Early on, restlessness and involuntary muscle spasms are the most common issues. With long-term use, the bigger worry is tardive dyskinesia, a condition involving repetitive, involuntary movements of the face and tongue that can become permanent. Women, older adults, and people with diabetes face the highest risk of these movement disorders.¹ For this reason, guidelines generally recommend keeping treatment courses short, usually no longer than twelve weeks.

Domperidone is a related dopamine antagonist used widely outside the United States. It does not cross the blood-brain barrier as readily, so the neurological side effects are much less common. However, domperidone carries its own concern: it can prolong the QT interval on an electrocardiogram, raising the risk of abnormal heart rhythms in susceptible people. In several countries, it is available over the counter at low doses for short-term nausea relief.

Serotonin 5-HT4 Receptor Agonists

Serotonin plays a major role in gut function. Most of the body’s serotonin is actually made in the intestinal lining, and it helps coordinate the wave-like muscle contractions that push food along. Drugs that activate the 5-HT4 receptor subtype stimulate this process, making them effective prokinetics for the lower GI tract in particular.

Prucalopride is the standout in this class. It is a highly selective 5-HT4 agonist approved for chronic constipation in many countries. Multiple large clinical trials have shown that it speeds up colonic transit, improves bowel function, and reduces constipation-related symptoms, with benefits maintained for up to two years in follow-up studies.² An integrated analysis of trial data found that the standard 2 mg dose reduced colonic transit time by about 12 hours compared with placebo. Among patients who had especially slow transit at baseline, the improvement was even larger, roughly 23 hours faster, and over a third of those patients achieved a normal transit time by the end of treatment.³

Selectivity matters in this drug class because of a troubled history. Two earlier, less selective 5-HT4 agonists ran into serious cardiovascular problems. Cisapride caused dangerous heart rhythm disturbances linked to QT prolongation and was withdrawn from most markets. Tegaserod was associated with heart attacks and strokes, likely because it also acted on other serotonin receptor subtypes involved in blood vessel constriction.⁴ Prucalopride’s tight selectivity for the 5-HT4 receptor was designed to avoid these off-target effects, and cardiovascular safety data from its trials has been reassuring.

Motilin Receptor Agonists

Erythromycin is an antibiotic, but at sub-antimicrobial doses it mimics the gut hormone motilin and triggers strong stomach contractions. This makes it one of the fastest-acting prokinetics available for upper GI problems. It stimulates both the upper portion and the lower pumping region of the stomach while simultaneously relaxing the pyloric sphincter, the muscular valve at the stomach’s outlet. That combination is particularly useful when the goal is to speed gastric emptying.⁵

The problem is durability. The motilin receptor downregulates after about four weeks of regular dosing, meaning the drug progressively loses its effectiveness. This phenomenon, called tachyphylaxis, limits erythromycin to short-term or intermittent use. In practice, many gastroenterologists prescribe it as a bridge while figuring out a longer-term strategy. Using it at full antibiotic doses for motility also raises concerns about promoting antibiotic resistance, so lower doses are preferred when the drug is given purely as a prokinetic.

Ghrelin Receptor Agonists

Ghrelin is the “hunger hormone,” but it also directly stimulates stomach contractions. Relamorelin is a synthetic peptide that activates the ghrelin receptor and has been studied specifically in diabetic gastroparesis. A meta-analysis of trials found that relamorelin produced a statistically significant improvement in gastric emptying compared with placebo in this population.⁶ Phase 2 data also showed improvements in gastroparesis symptoms alongside the faster emptying times.⁷

Relamorelin has not yet received FDA approval, and its development has had a bumpy path, but it represents a genuinely different mechanism from existing options. Because ghrelin receptors are concentrated in the stomach rather than spread throughout the nervous system, the hope is that ghrelin-based drugs will cause fewer systemic side effects than dopamine antagonists. Whether relamorelin or a related compound eventually reaches the market remains an open question.

Acetylcholinesterase Inhibitors

Neostigmine works by preventing the breakdown of acetylcholine, the neurotransmitter that directly drives gut muscle contractions. More acetylcholine hanging around means stronger, more coordinated peristalsis. This drug is not used for everyday constipation; its niche is acute colonic pseudo-obstruction, also known as Ogilvie syndrome, a condition where the colon becomes massively dilated without any physical blockage. It is most often seen in hospitalized patients after surgery, trauma, or serious illness.

In a landmark randomized trial, 10 of 11 patients who received intravenous neostigmine had prompt colon decompression, compared with none of the patients on placebo. The median time to response was just four minutes.⁸ More recent data from neurocritical care patients confirmed the effect: all patients had bowel movements after the first injection, with a median time to defecation of about two hours, and the dilated colon shrank significantly on imaging.⁹ Neostigmine requires cardiac monitoring during administration because it can slow the heart rate, so it is strictly an in-hospital drug.

Direct Cholinergic Agents

Bethanechol takes a more direct approach than neostigmine. Instead of preventing acetylcholine breakdown, it mimics acetylcholine by directly stimulating muscarinic receptors on smooth muscle. It was historically used to treat urinary retention and has a secondary role in GI motility, particularly in the esophagus. In patients with severely weak esophageal contractions, bethanechol significantly increased contraction pressures and improved the ability of the esophagus to move a swallowed bolus toward the stomach.¹⁰ Its use in modern gastroenterology is relatively uncommon, largely because newer agents with fewer side effects have taken its place for most lower-GI indications. Side effects like sweating, abdominal cramps, and salivation reflect the broad nature of cholinergic stimulation.

Secretory Agents That Also Speed Transit

Not every drug that treats constipation works by directly making the gut contract harder. Some increase intestinal fluid secretion, which in turn physically stimulates motility. The distinction matters because these drugs reach the gut lining from the inside, without being absorbed into the bloodstream in meaningful amounts, making systemic side effects rare.

Lubiprostone activates a specific chloride channel in the cells lining the intestine. When chloride flows into the gut lumen, water follows, softening stool and increasing the volume of intestinal contents. That extra volume stretches the gut wall and triggers the natural reflexes that move things along. Studies in healthy volunteers showed that lubiprostone accelerated both small bowel and colonic transit.¹¹ It is FDA-approved for chronic idiopathic constipation, irritable bowel syndrome with constipation in women, and opioid-induced constipation. An interesting wrinkle is that while it speeds small bowel and colonic transit, it actually slows gastric emptying somewhat, so it is primarily useful for lower-GI complaints.¹²

Linaclotide and plecanatide belong to a related but distinct class. They activate a receptor called guanylate cyclase-C on the intestinal surface, which increases fluid secretion through a different signaling pathway. Linaclotide has also been shown to increase intestinal motility by activating sensory and motor neurons in the colon, so it has a dual effect: more fluid and more propulsion.¹³ Both are approved for chronic idiopathic constipation and irritable bowel syndrome with constipation. The most common side effect is diarrhea, which makes sense given their mechanism.

Peripherally Acting Opioid Antagonists

Opioid painkillers are one of the most common causes of slowed gut motility. They activate mu-opioid receptors throughout the GI tract, suppressing the normal muscle contractions that move food and waste. Peripherally acting mu-opioid receptor antagonists, often abbreviated PAMORAs, were developed to block this effect in the gut without interfering with pain relief in the brain.¹⁴

Drugs in this class include methylnaltrexone, naloxegol, and naldemedine. They are approved for opioid-induced constipation in adults on chronic opioid therapy. Their role in postoperative ileus, the temporary gut shutdown that often follows abdominal surgery, is more nuanced. A systematic review found that PAMORAs may help with both opioid-induced constipation and postoperative ileus, but noted inconsistency across studies and relatively low overall quality of evidence, making firm conclusions difficult.¹⁵ In practice, they are most clearly useful when the constipation is directly attributable to opioid use and less clearly beneficial for the complex ileus that follows major surgery.

Combination Therapy in Hospital Settings

In intensive care units, slowed gut motility is extremely common and creates a real clinical problem: patients who cannot tolerate tube feeding become malnourished, which slows recovery from whatever put them in the ICU in the first place. The standard approach is to use erythromycin, metoclopramide, or both.

A clinical trial comparing the combination of erythromycin plus metoclopramide to erythromycin alone found that the dual regimen worked better. After 24 hours of treatment, patients on the combination had significantly lower residual stomach volumes, received more daily calories, and needed fewer post-pyloric feeding tubes. Tachyphylaxis still developed in both groups, but it was less pronounced with the combination.¹⁶ Diarrhea is the main trade-off: it can occur in nearly half of patients on dual prokinetic therapy, though it resolves once the drugs are stopped and does not appear linked to intestinal infection.¹⁷

Newer and Emerging Agents

Acotiamide targets a different part of the motility puzzle. It inhibits the breakdown of acetylcholine specifically at the nerve-muscle junction in the stomach wall, enhancing both the stomach’s ability to relax and accommodate a meal and its ability to empty afterward. In a randomized trial of patients with functional dyspepsia, the gastric accommodation rate was roughly five times higher in the acotiamide group than in the placebo group after a standardized liquid meal, and gastric emptying also sped up significantly.¹⁸ Acotiamide is approved in Japan for functional dyspepsia but has not reached the U.S. or European markets.

Elobixibat takes a completely novel approach. It blocks a transporter in the small intestine that normally recycles bile acids back into the body. When more bile acids escape into the colon, they directly stimulate colonic contractions and fluid secretion, effectively acting as a natural laxative signal that the drug amplifies.¹⁹ It is approved for chronic constipation in Japan and is being studied elsewhere. The concept of hijacking bile acid signaling to drive motility is appealing because it leverages an existing physiological pathway rather than introducing an entirely foreign stimulus.

Do Any Natural Substances Work?

Ginger has the most credible evidence among herbal remedies. In a controlled study of patients with functional dyspepsia, those who took ginger capsules before a test meal emptied their stomachs faster than those who took placebo, with the half-emptying time dropping from about 16 minutes to about 12 minutes. There was also a trend toward more frequent stomach contractions, though it just missed statistical significance.²⁰ The effect is modest, and the same study found no improvement in actual symptoms, which tempers the enthusiasm. Still, ginger is inexpensive and well tolerated, which makes it a reasonable first step for mild complaints before escalating to prescription drugs.

Other herbal preparations marketed as digestive aids, including artichoke extract, peppermint oil, and the multi-herb formulation STW 5 (Iberogast), have varying degrees of evidence. Peppermint oil is better studied for its antispasmodic properties in irritable bowel syndrome than for prokinetic effects specifically. None of these herbal agents have anywhere near the potency of prescription prokinetics, and they should not substitute for medical treatment in conditions like gastroparesis or colonic pseudo-obstruction.

How Doctors Measure Whether These Drugs Are Working

Knowing whether a prokinetic drug is actually doing its job requires objective measurement of transit time, not just asking a patient if they feel better. The gold standard for gastric emptying is scintigraphy: you eat a meal containing a tiny amount of a radioactive tracer, and a camera tracks how quickly it leaves your stomach over four hours. A wireless motility capsule, a swallowable sensor about the size of a large vitamin, can measure pressure, pH, and temperature as it travels through the entire GI tract, providing transit data for the stomach, small bowel, and colon in a single test. For colonic transit specifically, the traditional method involves swallowing radio-opaque markers and taking an abdominal X-ray five days later to count how many remain.²¹

These tests are not just academic exercises. Knowing exactly where transit is slow guides drug selection. A patient whose stomach empties normally but whose colon is sluggish would benefit from prucalopride or linaclotide, not erythromycin. Conversely, a patient with confirmed delayed gastric emptying might respond best to metoclopramide or erythromycin. When the whole GI tract is slow, combination strategies or agents with broad regional effects become more relevant.

The Gut Microbiome Connection

An emerging area of research involves the relationship between gut bacteria and motility. Certain bacterial species produce neurotransmitters, including GABA, that are active in the enteric nervous system and may modulate intestinal contractions.²² Serotonin produced by enteric neurons also appears essential for normal baseline gut motility and for the survival of dopamine-producing neurons within the gut’s own nervous system.²³ This creates a two-way street: motility affects which bacteria thrive (because transit time determines how long microbes have to colonize a given stretch of intestine), and the microbes in turn produce chemicals that influence motility.

What this means for treatment is still speculative. Probiotics marketed for digestive regularity have not yet shown the kind of consistent, robust prokinetic effects that would put them in the same conversation as prescription drugs. But the science suggests that future therapies might target the microbial ecosystem as a way to restore normal motility, rather than stimulating the muscles or nerves directly. For now, the practical takeaway is that anything drastically altering your gut flora, like a course of broad-spectrum antibiotics, can disrupt motility in ways that outlast the medication itself.